Literature DB >> 30239314

11C-methionine-18F-FDG dual-PET-tracer-based target delineation of malignant glioma: evaluation of its geometrical and clinical features for planning radiation therapy.

Takero Hirata1,2, Manabu Kinoshita3,4, Keisuke Tamari1, Yuji Seo1, Osamu Suzuki1, Nobuhide Wakai5, Takamune Achiha3,4, Toru Umehara3, Hideyuki Arita3, Naoki Kagawa3, Yonehiro Kanemura6, Eku Shimosegawa7, Naoya Hashimoto3, Jun Hatazawa7, Haruhiko Kishima3, Teruki Teshima2, Kazuhiko Ogawa1.   

Abstract

OBJECTIVE: It is important to correctly and precisely define the target volume for radiotherapy (RT) of malignant glioma. 11C-methionine (MET) positron emission tomography (PET) holds promise for detecting areas of glioma cell infiltration: the authors' previous research showed that the magnitude of disruption of MET and 18F-fluorodeoxyglucose (FDG) uptake correlation (decoupling score [DS]) precisely reflects glioma cell invasion. The purpose of the present study was to analyze volumetric and geometrical properties of RT target delineation based on DS and compare them with those based on MRI.
METHODS: Twenty-five patients with a diagnosis of malignant glioma were included in this study. Three target volumes were compared: 1) contrast-enhancing core lesions identified by contrast-enhanced T1-weighted images (T1Gd), 2) high-intensity lesions on T2-weighted images, and 3) lesions showing high DS (DS ≥ 3; hDS). The geometrical differences of these target volumes were assessed by calculating the probabilities of overlap and one encompassing the other. The correlation of geometrical features of RT planning and recurrence patterns was further analyzed.
RESULTS: The analysis revealed that T1Gd with a 2.0-cm margin was able to cover the entire high DS area only in 6 (24%) patients, which indicates that microscopic invasion of glioma cells often extended more than 2.0 cm beyond a Gd-enhanced core lesion. Insufficient coverage of high DS regions with RT target volumes was suggested to be a risk for out-of-field recurrence. Higher coverage of hDS by T1Gd with a 2-cm margin (i.e., higher values of "[T1Gd + 2 cm]/hDS") had a trend to positively impact overall and progression-free survival. Cox regression analysis demonstrated that low coverage of hDS by T1Gd with a 2-cm margin was predictive of disease recurrence outside the Gd-enhanced core lesion, indicative of out-of-field reoccurrence.
CONCLUSIONS: The findings of this study indicate that MRI is inadequate for target delineation for RT in malignant glioma treatment. Expanding the treated margins substantially beyond the MRI-based target volume may reduce the risk of undertreatment, but it may also result in unnecessary irradiation of uninvolved regions. As MET/FDG PET-DS seems to provide more accurate information for target delineation than MRI in malignant glioma treatment, this method should be further evaluated on a larger scale.

Entities:  

Keywords:  11C-methionine positron emission tomography; DS = decoupling score; FDG = 18F-fluorodeoxyglucose; FDG-PET; HR = hazard ratio; Met = 11C-methionine; NCC = National Cancer Center Research Institute; ONH = Osaka National Hospital; OS = overall survival; PET = positron emission tomography; PFS = progression-free survival; ROI = region of interest; RT = radiotherapy; T/N = tumor to normal tissue; VOI = voxel of interest; malignant glioma; oncology; qPCR = quantitative polymerase chain reaction; radiation therapy

Mesh:

Substances:

Year:  2019        PMID: 30239314     DOI: 10.3171/2018.4.JNS1859

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  5 in total

1.  Contribution of PET imaging to radiotherapy planning and monitoring in glioma patients - a report of the PET/RANO group.

Authors:  Norbert Galldiks; Maximilian Niyazi; Anca L Grosu; Martin Kocher; Karl-Josef Langen; Ian Law; Giuseppe Minniti; Michelle M Kim; Christina Tsien; Frederic Dhermain; Riccardo Soffietti; Minesh P Mehta; Michael Weller; Jörg-Christian Tonn
Journal:  Neuro Oncol       Date:  2021-06-01       Impact factor: 12.300

2.  Efficacy and Safety of Temozolomide Combined with Radiotherapy in the Treatment of Malignant Glioma.

Authors:  Shoufeng Wei; Junde Li
Journal:  J Healthc Eng       Date:  2022-02-15       Impact factor: 2.682

3.  Artificial Intelligence Algorithm-Based Positron Emission Tomography (PET) and Magnetic Resonance Imaging (MRI) in the Treatment of Glioma Biopsy.

Authors:  Wei Wei; Liujia Ma; Liying Yang; Rong Lu; Cong Xi
Journal:  Contrast Media Mol Imaging       Date:  2022-03-23       Impact factor: 3.161

4.  Determining optimal clinical target volume margins in high-grade glioma based on microscopic tumor extension and magnetic resonance imaging.

Authors:  Shulun Nie; Yufang Zhu; Jia Yang; Tao Xin; Song Xue; Xianbin Zhang; Jujie Sun; Dianbin Mu; Yongsheng Gao; Zhaoqiu Chen; Xingchen Ding; Jinming Yu; Man Hu
Journal:  Radiat Oncol       Date:  2021-06-07       Impact factor: 3.481

5.  Prediction and Visualization of Non-Enhancing Tumor in Glioblastoma via T1w/T2w-Ratio Map.

Authors:  Shota Yamamoto; Takahiro Sanada; Mio Sakai; Atsuko Arisawa; Naoki Kagawa; Eku Shimosegawa; Katsuyuki Nakanishi; Yonehiro Kanemura; Manabu Kinoshita; Haruhiko Kishima
Journal:  Brain Sci       Date:  2022-01-12
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.